Clinical-stage biopharmaceutical firm Deciphera Pharmaceuticals has commenced a Phase I clinical trial of DCC-3014 for the treatment of patients with advanced malignancies.

Equipped with the firm’s Switch Control Inhibitor platform, DCC-3014 is a highly selective, small-molecule colony stimulating factor 1 receptor (CSF1R) inhibitor designed to act as a highly specific macrophage immunomodulatory agent.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The multi-centre Phase I trial will evaluate the safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of DCC-3014 in approximately 55 patients across both dose-escalation and expansion phases.

Deciphera president and chief executive officer Michael Taylor said: “We are excited to initiate this first-in-human Phase I clinical trial of DCC-3014, our small molecule switch control inhibitor of CSF1R.

“Preclinical data from a number of cancer models have demonstrated that DCC-3014 has potent macrophage checkpoint inhibitory activity.

“We believe DCC-3014 has great potential as a novel immunomodulatory agent and an important new therapy for cancer patients.”

“We believe DCC-3014 has great potential as a novel immunomodulatory agent and an important new therapy for cancer patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to Deciphera chief medical officer Oliver Rosen, DCC-3014 blocks immune checkpoints of macrophage associated with the tumour microenvironment and was found to have additive or synergistic immunomodulatory activity in combination with PD-1 inhibitor in multiple preclinical models.

The drug has also demonstrated a potent inhibition of the CSF1R in the models.

Deciphera primarily develops therapeutic agents to address the drug resistance mechanisms that mitigate the rate and / or durability of response in cancer patients.

The agents are designed to target enzymes called kinases, which are reported to be involved in the growth and spread of several cancers.